Linked Life Data

15365766

Source:http://linkedlifedata.com/resource/pubmed/id/15365766

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2004-11-4
pubmed:abstractText
Irinotecan, a topoisomerase I inhibitor, is an effective agent for non-small-cell lung cancer (NSCLC). To determine the efficacy and toxicity of irinotecan and carboplatin, we conducted a phase II study in 61 patients with advanced NSCLC.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0344-5704
pubmed:author
pubmed:issnType
Print
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
573-7
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
pubmed:affiliation
Division of Respiratory Disease, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Okayama, Japan, mifukuda258@nifty.com.
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II